PTCT:NSD-PTC Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 45.93

Change

0.00 (0.00)%

Market Cap

USD 3.51B

Volume

0.78M

Analyst Target

USD 60.30
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 65.38B
ARGX argenx NV ADR

N/A

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 32.75B
ONC BeiGene, Ltd.

N/A

USD 27.70B
SMMT Summit Therapeutics PLC

N/A

USD 27.07B
RPRX Royalty Pharma Plc

N/A

USD 18.40B
INSM Insmed Inc

N/A

USD 11.84B
INCY Incyte Corporation

N/A

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 11.29B

ETFs Containing PTCT

MSGR 6.14 % 0.00 %

N/A

N/A
IBRN iShares Trust - iShares N.. 4.03 % 0.00 %

N/A

USD 3.31M
SBIO ALPS Medical Breakthrough.. 3.18 % 0.50 %

N/A

USD 0.08B
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

N/A
BIOT 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.75% 75% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.75% 75% C 68% D+
Trailing 12 Months  
Capital Gain 23.47% 83% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.47% 83% B 79% B-
Trailing 5 Years  
Capital Gain -9.25% 74% C 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.25% 74% C 36% F
Average Annual (5 Year Horizon)  
Capital Gain 2.14% 56% F 50% F
Dividend Return 2.14% 55% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.30% 69% C- 41% F
Risk Adjusted Return 4.93% 57% F 42% F
Market Capitalization 3.51B 93% A 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.